ImmunityBio(NASDAQ) IBRX

ImmunityBio, Inc. makes medicines that help the body fight cancer. Its treatments use the patient's own immune system to attack diseases. These therapies aim to provide long-lasting protection against serious illnesses.

A Toolkit for the Immune System

• ANKTIVA: IL-15 receptor superagonist used with other treatments for bladder cancer; primary driver of net product revenue.
• Bladder Cancer Therapies: Treatments for adult patients with bladder cancer who no longer respond to standard bacterial therapy.
• Lung Cancer Combinations: Investigational treatments for advanced lung cancer used alongside checkpoint inhibitors.
• Cell Therapies: Natural killer cell platforms designed to recognize and kill cancer cells.
• Infectious Disease Vaccines: Research programs targeting viruses like HIV and SARS-CoV-2.

Global Growth and Partnerships

• Entered an exclusive agreement with JBL to develop and commercialize Tokyo-172 BCG in the U.S.
• Received accelerated conditional approval for ANKTIVA in lung cancer from Saudi Arabian regulators in 2026.
• Expanded its global footprint to 34 countries following marketing authorizations in the United Arab Emirates.
• Launched commercial distribution of ANKTIVA in the U.S. during May 2024.
• Partnered with Serum Institute to supply rBCG for use in clinical development programs.

How It Stands Out

ImmunityBio utilizes its Cancer BioShield platform to activate both innate and adaptive immune systems to create immunological memory. The company maintains strategic partnerships with organizations like the National Cancer Institute to advance its clinical trials.

The Financial Scorecard

• Net product revenue was $50.7 million in the three-month period ended June 30, 2026, up 92% year over year.
• Total research and development expense was $60.8 million in the second quarter of 2026, up 10% year over year.
• Net loss reached $230.4 million for the three-month period ended June 30, 2026, compared to $92.6 million in 2025.
• Cash and marketable securities totaled $357.4 million as of June 30, 2026, up from $242.8 million in Dec. 2025.
• Market cap was $8.1 billion, according to the provided company data.

Evolution of the Business

ImmunityBio has transitioned from a clinical-stage research firm to a commercial provider of cancer immunotherapies. Its expansion into international markets and ongoing clinical trials reflect a strategy focused on diversifying its pipeline.